How to monitor the effectiveness of imatinib/Gleevec treatment?

Imatinib/Gleevec (Imatinib) is an important targeted therapy drug, widely used in the treatment of chronic myelogenous leukemia (CML), gastrointestinal stromal tumor (GIST) and other malignant tumors. It prevents the proliferation of cancer cells by inhibiting the activity of BCR-ABL tyrosine kinase. The clinical efficacy of imatinib is significant. However, due to individual patient differences, possible side effects during treatment, and different treatment goals for different types of cancer, monitoring the treatment effect has become a crucial link in the treatment process. Effective monitoring can help doctors promptly evaluate the efficacy and side effects of drugs and adjust treatment plans to optimize patient outcomes.

Routine clinical evaluation and biochemical marker monitoring are essential when using imatinib. For patients with chronic myelogenous leukemia, the key to monitoring treatment effects lies in hematological indicators and molecular biological markers.

1. Hematological evaluation: Patients with chronic myelogenous leukemia usually undergo routine blood tests to monitor changes in white blood cell count, platelet count, and red blood cell count. In the early stages of treatment, imatinib can effectively reduce the number of white blood cells and improve bone marrow function. Therefore, doctors evaluate the success of treatment based on the patient's hematology results. Normalized white blood cell and platelet counts are often a sign that treatment is responding.

2. Molecular biology monitoring: In addition to hematology evaluation, molecular biology monitoring is crucial forthe evaluation of treatment effects in CML patients. Imatinib achieves therapeutic effects by inhibiting the tyrosine kinase activity produced by the BCR-ABL fusion gene. Therefore, the detection of BCR-ABL gene fusion (usually through real-time quantitative PCR technology) has become an important indicator for judging the therapeutic effect of imatinib. By measuring the amount of BCR-ABL transcripts, it is possible to assess whether the treatment is effective. In the early stages of treatment, the transcription level of the BCR-ABL gene usually decreases significantly, and the patient's response can be divided into complete molecular response (CMR), molecular response (MR) and other levels, which is crucial for evaluating the effect of treatment.

In addition to the monitoring of hematology and molecular markers, changes in patients' clinical symptoms are also important indicators for monitoring the effectiveness of treatment. During imatinib treatment, whether the patient's symptoms are relieved directly reflects the effect of the treatment. For patients with chronic myelogenous leukemia, signs that treatment is effective often include improvements in symptoms such as fatigue and bleeding tendencies. In addition, the symptoms of patients with gastrointestinal stromal tumors (such as abdominal pain, nausea, etc.) will gradually improve as the tumors shrink.

Resistance monitoring to imatinib is also a part of the treatment process that cannot be ignored. Some patients may develop drug resistance due to genetic mutations or insufficient drug concentration, which may manifest as worsening of clinical symptoms or tumor growth. Common resistance mechanisms include mutations in the BCR-ABL gene or other changes related to drug targets. At this time, the patient's BCR-ABL transcript levels may rise again, or tumor progression may appear on imaging. Therefore, timely monitoring of these indicators is an important means to ensure the effectiveness of treatment.

Imatinib treatment is usually long-term, especially for patients with chronic myeloid leukemia, where treatment often needs to be maintained for many years or even lifelong. During the treatment process, doctors should regularly adjust the monitoring plan based on the patient's condition and treatment response. These monitoring are not limited to initial efficacy assessment, but also include long-term follow-up and side-effect management.

Reference materials:https://www.gleevec.com/